Where are we with a vaccine? Here’s the latest.
Johnson & Johnson’s investigational COVID-19 vaccine entered Phase 3 clinical trials this week, making it the fourth vaccine candidate in the U.S. to do so and providing additional details that can help investors differentiate the pool of late-stage coronavirus vaccines.
One of the unique characteristics of this race to develop a vaccine is how different the candidates are, down to the type of vaccine. Dosing: J&J’s vaccine is the only single-dose vaccine to enter late-stage studies in the U.S., though separate clinical trials in Northern Ireland and the U.K. will test a two-dose regimen. The other three candidates require two doses, spaced between roughly three to four weeks apart, depending on the vaccine. “The single dose could be a source of commercial differentiation, and also means [J&J’s] pivotal trial could read out more quickly ,” Bernstein’s Vincent Chen wrote on Sept. 17.
The need to refrigerate vaccines generally has long been an issue for vaccination programs, according to Casper. ”Even in highly industrialized countries…it is very challenging to keep vaccines refrigerated, just at refrigeration temperatures,” he said.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Novavax Researcher Says No Chance Of A 'Shortcut' In Vaccine SafetyVaccine maker Novavax is starting a large coronavirus vaccine trial in the U.K. Gregory Glenn, the company's president of research and development, talks with NPR about how vaccines are tested.
Weiterlesen »
Novavax initiates late-stage COVID-19 vaccine trial in UKNovavax Inc on Thursday started a late-stage trial of its experimental COVID-19 vaccine in the United Kingdom in partnership with the government's Vaccines Taskforce, sending the company's shares up 6% after the bell.
Weiterlesen »
Novavax initiates late-stage COVID-19 vaccine trial in UKNovavax Inc on Thursday started a late-stage trial of its experimental COVID-19 vaccine in the United Kingdom in partnership with the government's Vaccines Taskforce, sending the company's shares up 6% after the bell.
Weiterlesen »
Sanofi isn't cutting corners in coronavirus vaccine development despite acceleration, CEO says'We don't feel pressure. We feel pressure to get it right and maintain the standards and to play a big part in helping people get back to normal,' Sanofi CEO Paul Hudson told CNBC.
Weiterlesen »
China says WHO gave blessing for coronavirus vaccine emergency use programmeThe World Health Organization gave China its support and understanding to start administering experimental coronavirus vaccines to people while clinical trials were still underway, a Chinese health official said on Friday.
Weiterlesen »
UK pledges £500m to global Covid vaccine schemeThe PM will call on world leaders to set aside differences as he sets out plans to prevent future pandemics.
Weiterlesen »